Rocket Pharmaceuticals Inc (RCKT) concluded trading on Thursday at a closing price of $6.72, with 6.49 million shares of worth about $43.6 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -60.11% during that period and on May 15, 2025 the price saw a gain of about 11.07%. Currently the company’s common shares owned by public are about 106.75M shares, out of which, 99.77M shares are available for trading.
Stock saw a price change of -4.47% in past 5 days and over the past one month there was a price change of 2.99%. Year-to-date (YTD), RCKT shares are showing a performance of -46.50% which decreased to -70.87% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.55 but also hit the highest price of $26.98 during that period. The average intraday trading volume for Rocket Pharmaceuticals Inc shares is 2.70 million. The stock is currently trading -4.94% below its 20-day simple moving average (SMA20), while that difference is down -6.13% for SMA50 and it goes to -48.71% lower than SMA200.
Rocket Pharmaceuticals Inc (NASDAQ: RCKT) currently have 106.75M outstanding shares and institutions hold larger chunk of about 96.74% of that.
The stock has a current market capitalization of $724.53M and its 3Y-monthly beta is at 0.87. It has posted earnings per share of -$2.63 in the same period. It has Quick Ratio of 9.19 while making debt-to-equity ratio of 0.06. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RCKT, volatility over the week remained 13.99% while standing at 9.95% over the month.
Stock’s fiscal year EPS is expected to rise by 15.41% while it is estimated to increase by 27.79% in next year. EPS is likely to grow at an annualized rate of 43.23% for next 5-years, compared to annual growth of -11.60% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BMO Capital Markets on March 12, 2025 offering an Outperform rating for the stock and assigned a target price of $50 to it. Coverage by Wedbush stated Rocket Pharmaceuticals Inc (RCKT) stock as an Outperform in their note to investors on December 30, 2024, suggesting a price target of $32 for the stock. Stock get a Neutral rating from Goldman on April 02, 2024.
